Evidence map›Paper›PMID 40342439›Full record

ArticleCureus2025

Utility of the Base Editing System for Introducing Drug-Resistant Gene Mutations Into Human Leukemia Cellular Models.

Thao Nguyen, Minori Tamai, Shinichi Fujisawa, Akiko Nagamachi, Keiko Kagami, Chiaki Komatsu, Shotaro Iwamoto, Toshiya Inaba, Takanori Teshima, Takeshi Inukai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Thao NguyenPediatrics, University of Yamanashi, Chuo, JPN.
Minori TamaiPediatrics, Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Chuo, JPN.
Shinichi FujisawaLaboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, JPN.
Akiko NagamachiMolecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, JPN.
Keiko KagamiGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Chuo, JPN.
Chiaki KomatsuGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Chuo, JPN.
Shotaro IwamotoPediatrics, Mie University Graduate School of Medicine, Tsu, JPN.
Toshiya InabaMolecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, JPN.
Takanori TeshimaLaboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, JPN.
Takeshi InukaiPediatrics, Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Chuo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Recent genomic analyses of poor prognostic and relapsed leukemia have revealed the involvement of diverse gene mutations in treatment resistance. These gene mutations are classified into two groups: mutations involving resistance to specific agents such as the

Indexed as

base editingbcr::abl1drug resistancegenome editingleukemiamutationtp53

Identifiers

PMID40342439
PMCPMC12060998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.